Evidence map›Paper›PMID 35231609›Full record

ArticleInternational journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases2022

Performance evaluation of novel fluorescent-based lateral flow immunoassay (LFIA) for rapid detection and quantification of total anti-SARS-CoV-2 S-RBD binding antibodies in infected individuals.

Farah M Shurrab, Nadin Younes, Duaa W Al-Sadeq, Na Liu, Hamda Qotba, Laith J Abu-Raddad, Gheyath K Nasrallah

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.

0numbers the graph read from it
0cells of the map it votes in
23citing papers in PubMed
1.9field-weighted citation impact, top 14% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

23 citing papers in PubMed, 23 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Article
  6. Review
  7. Review
  8. Article
  9. Review
  10. Article
  11. Review
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 4 institutions in 3 countries.

Farah M ShurrabBiomedical Research Center, Qatar University, 2713, Doha, Qatar.
Nadin YounesBiomedical Research Center, Qatar University, 2713, Doha, Qatar; Department of Biomedical Science, College of Health Sciences, Member of QU Health, Qatar University, 2713, Doha, Qatar.
Duaa W Al-SadeqBiomedical Research Center, Qatar University, 2713, Doha, Qatar; College of Medicine, Member of QU Health, Qatar University, 2713, Doha, Qatar.
Na LiuShenzhen Mindray Bio-Medical Electronics Co., Ltd., Shenzhen, China.
Hamda QotbaDepartment of Clinical Research, Primary Health Care Centers, 26555, Doha, Qatar.
Laith J Abu-RaddadInfectious Disease Epidemiology Group, Weill Cornell Medicine-Qatar, Cornell University, Qatar Foundation-Education City, 24144, Doha, Qatar; World Health Organization Collaborating Centre for Disease Epidemiology Analytics on HIV/AIDS, Sexually Transmitted Infections, and Viral Hepatitis, Weill Cornell Medicine-Qatar, Cornell University, Qatar Foundation-Education City, 24144, Doha, Qatar; Department of Healthcare Policy and Research, Weill Cornell Medicine, Cornell University, New York, NY, 10065, USA.
Gheyath K NasrallahBiomedical Research Center, Qatar University, 2713, Doha, Qatar; Department of Biomedical Science, College of Health Sciences, Member of QU Health, Qatar University, 2713, Doha, Qatar. Electronic address: gheyath.nasrallah@qu.edu.qa.
Qatar University · QACornell University · USMindray (China) · CNPrimary Health Care · QA

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundA vast majority of the commercially available lateral flow immunoassay (LFIA) is used to detect SARS-CoV-2 antibodies qualitatively. Recently, a novel fluorescence-based lateral flow immunoassay (LFIA) test was developed for quantitative measurement of the total binding antibody units (BAUs) (BAU/mL) against SARS-CoV-2 spike protein receptor-binding domain (S-RBD).

aimThis study aimed to evaluate the performance of the fluorescence LFIA Finecare

methodsPlasma from 150 reverse trancriptase-PCR (RT-PCR)-confirmed positive individuals and 100 prepandemic samples were tested by Fincare

resultsFinecare

conclusionFinecare

Indexed as

COVID-19SARS-CoV-2Antibodies, NeutralizingAntibodies, ViralHumansImmunoassaySensitivity and SpecificitySpike Glycoprotein, CoronavirusAntibodies, NeutralizingAntibodies, ViralSpike Glycoprotein, Coronavirusspike protein, SARS-CoV-2COVID-19Fluorescence immunoassayLateral Flow AssaySARS-CoV-2Serology

Identifiers

PMID35231609
PMCPMC8882034
OpenAlexW4214769354

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.